^
    2d
    Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Yidafan (ivonescimab)
    5d
    A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=135, Not yet recruiting, Akeso
    New P1/2 trial
    |
    Yidafan (ivonescimab)
    5d
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    ZG005 • ZGGS18
    6d
    A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=35, Enrolling by invitation, Huai'an First People's Hospital
    New trial • pMMR
    |
    Lonsurf (trifluridine/tipiracil) • Yidafan (ivonescimab)
    6d
    A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    Dupert (fulzerasib) • Yidafan (ivonescimab)
    9d
    A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=330, Not yet recruiting, Genor Biopharma Co., Ltd.
    New P1 trial
    11d
    A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk (clinicaltrials.gov)
    P4, N=30, Recruiting, The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Yidafan (ivonescimab)
    11d
    Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open • Platinum sensitive
    |
    Lynparza (olaparib) • Yidafan (ivonescimab)
    12d
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Apr 2026 --> Jul 2026
    Trial completion date
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    Erbitux (cetuximab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    12d
    NSCLC: Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=536, Not yet recruiting, Akeso
    New P3 trial
    |
    docetaxel • Yidafan (ivonescimab)
    12d
    A Study of Ivonescimab in People With Endometrial and Cervical Cancers (clinicaltrials.gov)
    P2, N=50, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Yidafan (ivonescimab)
    12d
    Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    docetaxel
    18d
    A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Sun Yat-sen University
    New P2 trial • pMMR
    |
    capecitabine • oxaliplatin • Yidafan (ivonescimab)
    18d
    Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 (clinicaltrials.gov)
    P1, N=54, Recruiting, Shanghai Pushi Medical Science Co. Ltd | Not yet recruiting --> Recruiting | N=86 --> 54
    Enrollment open • Enrollment change
    18d
    Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors. (PubMed, Future Med Chem)
    Sorafenib was used as a reference drug...In silico studies confirmed its strong VEGFR-2 binding interactions. Thiadiazole-based derivatives, particularly compound 13b, exhibit potent VEGFR-2 inhibition, anti-proliferative effects, apoptosis induction, and anti-migratory activity, supporting their potential as promising anticancer agents.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
    |
    sorafenib
    19d
    A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Akeso
    New P1 trial
    |
    oxaliplatin • irinotecan • Kaitanni (cadonilimab) • Yidafan (ivonescimab)
    25d
    Irinotecan Hydrochloride Liposome Injection (II) Combined with Ivonescimab as Second-Line Therapy in Extensive-Stage Small Cell Lung Cancer: A Prospective Single-Arm Multicenter Study (ChiCTR2500099572)
    P=N/A, N=40, Not yet recruiting, Shengjing Hospital of China Medical University/The Second Hospital of Dalian Medical University; Shengjing Hospital of China Medical University
    New trial
    |
    Yidafan (ivonescimab)
    25d
    A Comparative Study on the Efficacy of Subretinal Injection of Anti-VEGF Agents versus Intravitreal Injection of Anti-VEGF Agents in the Treatment of Refractory Diabetic Macular Edema (ChiCTR2500098989)
    P=N/A, N=40, Not yet recruiting, Affiliated Eye Hospital of Nanchang University; Affiliated Eye Hospital of Nanchang University
    New trial
    25d
    Study on the Treatment of Persistent DME with Poor Response to Non-Surgical Therapy through the Combination of Anti-VEGF Drugs and Epiretinal Membrane Peeling Surgery (ChiCTR2500098999)
    P=N/A, N=40, Not yet recruiting, Shanghai Ninth People's Hospital， Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital， Shanghai JiaoTong University
    New trial
    25d
    Single-arm, single-center, exploratory clinical trial of AK112 combined with mFOLFOX6 chemotherapy for neoadjuvant treatment of locally advanced rectal adenocarcinoma (ChiCTR2500098601)
    P=N/A, N=40, Not yet recruiting, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College
    New trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Yidafan (ivonescimab)
    25d
    Perioperative Kadonilimab+Ivonescimab combined with salvage resection in patients with recurrent, resectable head and neck squamous cell carcinoma: A phase II Clinical Trial (ChiCTR2500096723)
    P2, N=32, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P2 trial
    |
    Yidafan (ivonescimab)
    25d
    AK112-RWS-IIT: Real-world clinical studies of Ivonescimab in locally advanced or metastatic non-squamous NSCLC with EGFR-TKI treatment failure (ChiCTR2500096483)
    P4, N=30, Recruiting, Higher Education Mega Center Hospital of Guangdong Provincial Hospital of Chinese Medicine; Higher Education Mega Center Hospital of Guangdong Provi
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR positive
    |
    Yidafan (ivonescimab)
    25d
    A prospective, open-label, single-arm, single-center phase II clinical study of Ivonescimab combined with chemotherapy in patients with advanced NSCLC and liver metastases. (ChiCTR2500096580)
    P2, N=30, Recruiting, North China University of Science and Technology Affiliated Hospital; North China University of Science and Technology Affiliated Hospital
    New P2 trial
    |
    Yidafan (ivonescimab)
    25d
    A single-arm, open, single-center Phase II study of Ivonescimab (AK112) combined with chemotherapy in the treatment of platinum-resistant recurrent ovarian cancer (ChiCTR2500095834)
    P2, N=40, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital
    New P2 trial • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1)
    |
    Yidafan (ivonescimab)
    25d
    Conversion therapy of ivonescimab in combination with arterial Infusion chemotherapy for initial inoperable high rectal cancer: a single-arm, single-center clinical study (ChiCTR2500095879)
    P2, N=20, Not yet recruiting, Tianjin Union Medical Center(The First Affiliated Hospital of Nankai University); Tianjin Union Medical Center(The First Affiliated Hospital of Nankai
    New P2 trial
    |
    Yidafan (ivonescimab)
    26d
    Ivonescimab (AK112) Plus Paclitaxel As Second-line Therapy in Patients with Advanced G/GEJ Cancer (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    paclitaxel • Cyramza (ramucirumab) • Yidafan (ivonescimab)
    1m
    A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1, N=150, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • pemetrexed • Aidixi (disitamab vedotin)
    1m
    PROTECT: Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma (clinicaltrials.gov)
    P3, N=57, Completed, Centre Hospitalier Universitaire de Nice | Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    1m
    Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors. (PubMed, Cancer Med)
    In patients with advanced solid tumors, ivonescimab monotherapy was well-tolerated and demonstrated a linear PK characteristics. PD profiles showed the promising potential of ivonescimab for the management of advanced solid tumors.
    PK/PD data • Journal
    |
    PD-1 (Programmed cell death 1)
    |
    Yidafan (ivonescimab)
    1m
    A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial
    |
    capecitabine • oxaliplatin
    1m
    ALTITUDE: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) (clinicaltrials.gov)
    P2, N=130, Recruiting, AbbVie | N=100 --> 130 | Trial completion date: Oct 2024 --> Sep 2026 | Trial primary completion date: May 2024 --> Feb 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    1m
    A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, RemeGen Co., Ltd.
    New P1 trial
    |
    carboplatin • paclitaxel • pemetrexed • Aidixi (disitamab vedotin)
    1m
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Aug 2025 --> Apr 2026
    Trial completion date
    |
    SIRPA (Signal Regulatory Protein Alpha)
    |
    Erbitux (cetuximab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    1m
    Endostar and chemoradiotherapy for advanced cervical cancer: comparing efficacy and prognosis. (PubMed, Am J Transl Res)
    Endostar combined with synchronous chemoradiotherapy for LACC significantly improves short-term treatment efficacy and long-term survival outcomes compared to chemoradiotherapy alone. This approach is safe and does not increase adverse effects, highlighting its potential as a superior treatment strategy.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Endostar (recombinant human endostatin)
    2ms
    Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=25, Recruiting, The First Hospital of Jilin University
    New P2 trial
    |
    Yidafan (ivonescimab)
    2ms
    AK117-203: A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Akeso | N=80 --> 120 | Trial completion date: Oct 2023 --> Dec 2026 | Trial primary completion date: Jan 2023 --> Jul 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    albumin-bound paclitaxel • Yidafan (ivonescimab) • ligufalimab (AK117)
    2ms
    AK104-221: An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=172, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Kaitanni (cadonilimab) • Yidafan (ivonescimab)
    2ms
    AK117-202: A Study of AK112 in Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=250, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Yidafan (ivonescimab) • ligufalimab (AK117)
    2ms
    A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Shanghai Junshi Bioscience Co., Ltd.
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • pemetrexed
    2ms
    Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. (PubMed, Lancet)
    Ivonescimab significantly improved PFS compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer. Therefore, ivonescimab might represent another treatment option in the first-line setting for PD-L1-positive advanced non-small cell lung cancer.
    Clinical • P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    2ms
    AK112-201: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (clinicaltrials.gov)
    P2, N=296, Recruiting, Akeso | Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • docetaxel • pemetrexed • Yidafan (ivonescimab)
    2ms
    Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=95, Recruiting, Lukas Biomedical Inc. | Trial primary completion date: Jun 2026 --> Dec 2026 | Trial completion date: Aug 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    LuLym-T (autologous activated lymphocytes)